emrusolmin (TEV- '286) / MODAG, Teva 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
emrusolmin (TEV- '286) / MODAG, Teva
TOPAS-MSA, NCT06568237: A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy Safety and Efficacy Study

Recruiting
2
200
US
TEV-56286, Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Multiple System Atrophy
05/27
06/27
NCT04685265: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease

Completed
1
70
Europe
anle138b, Placebo
MODAG GmbH, Aptuit, Quotient Sciences, Nottingham University Hospitals NHS Trust
Parkinson Disease
11/22
12/22
NCT05532358: A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)

Completed
1
54
Europe
anle138b (TEV-56286), Caffeine, Midazolam, Fluvoxamine, Fluvoxamine 100 mg QD for 5 days, TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine
MODAG GmbH, Aptuit, Quotient Sciences, Teva Pharmaceutical Industries, Ltd.
Healthy Volunteers
01/23
02/23

Download Options